<SEC-DOCUMENT>0001608936-25-000006.txt : 20250924
<SEC-HEADER>0001608936-25-000006.hdr.sgml : 20250924
<ACCEPTANCE-DATETIME>20250924163020
ACCESSION NUMBER:		0001608936-25-000006
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250922
FILED AS OF DATE:		20250924
DATE AS OF CHANGE:		20250924

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Chacko Jacob
		CENTRAL INDEX KEY:			0001608936
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39269
		FILM NUMBER:		251338828

	MAIL ADDRESS:	
		STREET 1:		C/O IGNYTA, INC.
		STREET 2:		11095 FLINTKOTE AVE., SUITE D
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oric Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001796280
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				471787157
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 388-5600

	MAIL ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-09242025_080916.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-09-22</periodOfReport>

    <issuer>
        <issuerCik>0001796280</issuerCik>
        <issuerName>Oric Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>ORIC</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001608936</rptOwnerCik>
            <rptOwnerName>Chacko Jacob</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ORIC PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>240 E. GRAND AVE., 2ND FLOOR</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>PRESIDENT AND CEO</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-09-22</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>125000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>10.7995</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>656419</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.</footnote>
        <footnote id="F2">Represents the weighted average share price of an aggregate total of 125,000 shares sold in the price range of $10.57 to $10.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.</footnote>
        <footnote id="F3">Includes 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.</footnote>
        <footnote id="F4">The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Christian Kuhlen, attorney-in-fact</signatureName>
        <signatureDate>2025-09-24</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
